Company: UPC
Filing Date: 2025-07-03
Form Type: 6-K
Source: 0001213900-25-061480
Chunk: 0

Company: Universe Pharmaceuticals INC
Filing Date: 2025-07-03
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐</div>

Financial Highlights for the Six Months Ended March 31, 2025

Universe Pharmaceuticals INC (the “Company”) hereby furnishes its financial results for the six months ended March 31, 2025.

|                                     |     | For the Six Months Ended March 31, |       |   |     |      |         |   |     |          |       |    |
| ($ millions, except per share data) |     |                               2025 |       |   |     | 2024 |         |   |     | % Change |       |    |
| Revenues                            |     |                                    |   9.2 |   |     |      |    12.9 |   |     |          | (29.0 | )% |
| Loss from operations                |     |                                    |  (2.3 | ) |     |      |    (1.7 | ) |     |          |  33.7 | %  |
| Net loss                            |     |                                    |  (3.3 | ) |     |      |    (2.4 | ) |     |          |  37.4 | %  |
| Loss per share                      |     |                                    | (9.44 | ) |     |      | (393.26 | ) |     |          | (97.6 | )% |

| ● | Revenues decreased by 29.0%                                                                                                                
 to $9.2 million for the six months ended March 31, 2025 from $12.9 million for